Value in Oncology

FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines

Eileen Koutnik-Fotopoulos

Value in Oncology

In a January 3, 2018, statement from FDA Commissioner Scott Gottlieb, MD, the FDA announced new steps to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer. These new steps are a part of the FDA’s ongoing implementation of the Drug Competition Action Plan. [ Read More ]

Active Surveillance the Least Costly Management Strategy for Low-Risk Prostate Cancer

Wayne Kuznar

Prostate Cancer, Solid Tumors, Value in Oncology

San Francisco, CA—Active surveillance is less costly than immediate treatment of low-risk prostate cancer, regardless of the specific treatment, according to findings from a cost analysis at a single institution presented at the 2018 Genitourinary Cancers Symposium. The cost-effectiveness of initial active surveillance compared with immediate treatment, as well as mitigation of treatment-related side effects, supports consideration of active surveillance as a management strategy in value-based care models, said lead investigator Franklin Gaylis, MD, FACS, Medical Director, Genesis Healthcare Partners (GHP), San Diego, who presented the study results. [ Read More ]

Rapid Adoption of Oncology Drugs Improves Survival

Chase Doyle

December 2017, Vol 8, No 5 - Value in Oncology

Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium. [ Read More ]

Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer

Wayne Kuznar

December 2017, Vol 8, No 5 - Value in Oncology

Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

Eileen Koutnik-Fotopoulos

June 2017, Vol 8, No 3 - Value in Oncology

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row. [ Read More ]

Comparing the Current Value Frameworks in Oncology

Meg Barbor, MPH

April 2017, Vol 8, No 2 - Value in Oncology

Chicago, IL—Escalating drug prices have put value frameworks in the spotlight, and the identification of the key questions and the audience addressed in each value framework is vital to understanding the value landscape, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program. [ Read More ]